The manufacturers of PAH treatment Flolan have confirmed it will be discontinued in the UK from 2028, and plans are being put in place to move patients to alternative medications over the next two years.
11 June 2026
The new PAH drug sotatercept has now been approved for use in eligible patients in England and Wales.
14 May 2026
The Scottish Medicines Consortium (SMC) has accepted the new PAH drug sotatercept for ‘restricted use’ in eligible patients in Scotland.
13 April 2026
A new PHA UK service aims to help people affected by pulmonary hypertension connect with others who truly understand.
7 April 2026
A new poetry competition launched by the PHA UK aims to help people in the pulmonary hypertension community explore the therapeutic benefits of writing.
31 March 2026 The Scottish Medicines Consortium (SMC) have announced that sotatercept, the ‘first in class’ PAH treatment, will not be commissioned for use by NHS Scotland at this stage.
9 February 2026